Cadrenal Therapeutics Bolsa (NASDAQ: CVKD)

Últimas noticias sobre Cadrenal Therapeutics (NASDAQ:CVKD) Bolsa

CADRENAL THERAPEUTICS INC

Cadrenal Therapeutics

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics Inc

TD Securities analyst Andrew Charles upgrades First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) from Hold to Buy and raises the price target from $21 to $22.

News

Upgrades

Price Target

Analyst Ratings

FWRG

TD Securities Upgrades First Watch Restaurant Gr to Buy, Raises Price Target to $22

Jones Trading analyst Jason Weaver maintains Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) from Hold to Hold.

Jones Trading Maintains Hold on Lument Finance Trustto Hold

Goldman Sachs analyst Kate McShane upgrades Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) from Neutral to Buy and raises the price target from $384 to $423.

ULTA

Goldman Sachs Upgrades Ulta Beauty to Buy, Raises Price Target to $423

Legendary rapper Snoop Dogg has been a passionate proponent of cryptocurrencies, with his interests ranging from popular coins like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38202011/jay-z-eminem-and-snoop-doggs-crypto-portfolios-revealed-who-owns-the-most">non-fungible tokens</a>.&nbsp;
What happened: The rap legend has grabbed attention for his several cryptocurrency-endorsing public remarks over the years.
During one such <a href="https://www.vanityfair.com/news/2021/04/snoop-dogg-talks-crypto-clubhouse-and-nfts">interview </a>with celebrity-focused magazine Vanity Fair in April 2021, the &#8220;Doggfather&#8221; admitted he was a firm Bitcoin believer.
"I believe in the technology, and I believe in the global connection it creates," the rapper said. "I'm not too caught up in the value of the coin because I've been around long enough to see things go up and go down, and I know it's here to stay."
These remarks were made during the early bull phase of the 2021 cycle when the apex cryptocurrency was nearing $60,000. This was also the time when the world was grappling with the COVID-19 pandemic.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/03/44555553/will-the-greatest-of-them-all-trump-memecoin-make-its-way-to-trump-media-etfs-polymarket-bettors-think-its-unlikely">&#8216;Greatest Of Them All&#8217; TRUMP Memecoin Headed for Trump Media ETFs? Polymarket Bettors Think It&#8217;s Unlikely</a>
"I don't see it as a pandemic fad, the pandemic just put gas on the fire," the rapper said about Bitcoin's meteoric growth during the period.
At the time, Bitcoin was trading at $59,098.88 apiece. Fast forward to the present, and the top digital asset is worth over $83,469.25, marking an increase of 41%. So, if you had invested $1,000 after the &#8220;Snoop Lion&#8217;s&#8221; remarks, it&#8217;d be worth $1,410 today. 
In fact, if anything, BTC has corrected from its January highs when it soared to $109,000, suggesting that Snoop Dogg was right on the money regarding the king cryptocurrency&#8217;s future.
Why It Matters: Details regarding Snoop Dogg&#8217;s Bitcoin stash remain unknown, although he has <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38202011/jay-z-eminem-and-snoop-doggs-crypto-portfolios-revealed-who-owns-the-most">spent </a>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) to acquire NFTs in the past. 
Earlier this year, the rapper <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43074504/crypto-firms-donate-millions-to-trump-inaugural-fund-host-unofficial-ball-featuring-snoop-dogg" target="_blank" rel="noreferrer noopener">performed at the first-ever inaugural Crypto Ball</a>&nbsp;leading up to President&nbsp;Donald Trump&#8216;s inauguration, drawing rebuke from some of his fans.
Price Action:  At the time of writing, Bitcoin was exchanging hands at $83,469.25, up 1.81% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Year-to-date, the cryptocurrency has dropped more than 11%.
Image Via Shutterstock
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44554819/elon-musk-dismisses-dogecoin-use-by-government-clears-the-air-on-doge-department-two-very-different-things">Elon Musk Dismisses Dogecoin Use By Government, Clears The Air On DOGE Department: &#8216;Two Very Different Things&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Entertainment

Markets

$BTC

$ETH

Snoop Dogg Once Said Bitcoin Wasn't A Pandemic Fad And Was Here To Stay — Fast Forward 4 Years And The Rap Legend's Words Ring True

WBB Securities analyst Steve Brozak reiterates Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) with a Strong Buy and maintains $12.5 price target.

Reiteration

MRKR

WBB Securities Reiterates Strong Buy on Marker Therapeutics, Maintains $12.5 Price Target

General

XCharge's GridLink System Receives UL 1973 And UL 9540A Certifications For Safety, Efficiency, And Grid Compliance

Airspan Networks Completes Corning Wireless Business Acquisition

RGTI

Defiance ETFs introduces RGTX To Provide Amplified Exposure To Rigetti Computing

Brand Engagement Network Inc. (BEN) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>), an innovator in AI-driven customer engagement solutions, has announced a strategic partnership with <a href="https://www.globenewswire.com/Tracker?data=HF9TjcZX2QP7B01Cx8QyeTpc75ZxQ_J91OT-3cXLA_AEceXDnz_SUTGsJZo5X__3_8WiVSC38VhCzijcr8FNnHMl0v4uNFIVx-77sf9N_qXN6VGaHTBGqfodsRtnom2VEJ6f4jMgxSkOd1GLLlf5aQ==">Swiss Life Global Solutions</a>. This collaboration will integrate BEN's innovative AI technology to help Swiss Life's clients and network partners implement generative AI-based solutions that enhance&nbsp;customer value via digital health, mental health and financial wellbeing services.
Swiss Life has taken thoughtful steps toward responsible AI adoption, grounded in its core values of trust, transparency, and long-term impact. In collaboration with BEN, the company published the white&nbsp;paper<a href="https://www.globenewswire.com/Tracker?data=vXE0VOM3DIyW0Cp0efuBIdj4JWjA7JdcJEyS2ZCItanAWUGA4f2Y8dICQYi8q9DJxTYIf0Zxbi2hgdXVobmUFnJ1CxGH8p5M-OoRLkkQV-v6z9uN6D04as4gd9_JjHX_jBZmEKFgNWbCpxNY0LHtM6d-2xIklEZ1g_xggAWXaMfhDYvOXSaflHfGjY1Uk9RqaqaY-sj5V_KTBR1jF3OfS7zix9yRqwj1ZZnsJouXVRP6hKl9UrYy9m0Iv1AaL77ZK4BHRjFk1Nj5XwAZsDHCNjbFD5fMyZ3BuM32kMCjNcrqDZ6bwXiFO2n-N_j5C1-XQwCwrbhikAYJrFBUfY9A9bjMex557nmL-7QVrimnvp_fTgGtNIFEiqirdc3rfcXneWI1vAnQs3HKlxujocsQZLwILVyzNzTN6EERNx5hFKP_SwPrW9GPL_peky_-gxZH-O4A8IqrB48UFfejh34jpS2h8XDlMtsz5O5Ji1-4jfwoaRHOlE98YO01k0oQX9ot_BwtF80N17hK2tzzJmG6efCCPuttwFB6W7OEuaNioXCSlZrTMIQqp3NR9bbOHV5NSpq5I0NsXUVVEJubNxzeFI-AhXUPvHwaXdv-XusZSEJOzkI-DmvdhClwzoHvtIXL4TOl0I1hA9IoYu5OYI_dKJxSj5TRDzMqyuHegDXaWaCzYI5TVJwwgxhgjzedS76HzEhwN0TUpKpTScPO5QTvxoSoCF8M7YhpZaciadxDBgpbXSrhsqwG_4Ad_CTVHcT1rfuZYjDHiKM8Bq4sKM7qpS9dhe9l-xPXRVogS1oSyJMlKPMLCCt8csjFezRID4jJ">"Time to Chat About the Bot: Is the Insurance Sector Ready for the AI Transformation?"</a>on June 13, 2024, outlining how AI can enhance customer engagement, improve compliance, and combat fraud. This new partnership builds on that shared vision, delivering secure and scalable AI solutions designed to support insurance operations.
Operating in over 85 countries, Swiss Life Global Solutions offers cross-border life insurance and employee benefits, backed by more than 250 billion Swiss francs (approximately $280 billion) in assets. Planned applications for the partnership include streamlining sales and enrollment, reducing call center volume, and enhancing member services with self-service tools for coverage details, policy updates, claims, and more.

BNAI

Brand Engagement Network Partners with Swiss Life to Enhance AI-driven Insurance Services

Goldman Sachs analyst Kate McShane upgrades AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) from Sell to Neutral and raises the price target from $3044 to $3811.

Goldman Sachs Upgrades AutoZone to Neutral, Raises Price Target to $3811

Guidance

DVLT

Datavault AI Sees FY26 Revenue Of $40M - $50M

Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) with a Buy and lowers the price target from $140 to $90.

PCVX

Needham Maintains Buy on Vaxcyte, Lowers Price Target to $90

DOOO

BRP To Sell 100% Of The Outstanding Shares Of Telwater To Yamaha Motor Australia

Goldman Sachs analyst Kate McShane downgrades Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) from Neutral to Sell and lowers the price target from $133 to $114.

Downgrades

Goldman Sachs Downgrades Genuine Parts to Sell, Lowers Price Target to $114

OpenAI has finalized a record-setting $40 billion funding round, boosting the company's valuation to $300 billion, with major investments from SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and other key backers.
What Happened: This financing round is the largest in history, according <a href="https://pitchbook.com/news/articles/openai-largest-vc-funding-round-40-billion">to</a> research firm PitchBook, and almost doubles OpenAI's previous valuation of $157 billion.
SoftBank led the latest funding round with an initial investment of $7.5 billion, accompanied by $2.5 billion from a group of investors, reported Bloomberg, citing a person familiar with the agreement.
See Also:&nbsp;<a href="https://in.benzinga.com/media/25/03/44566020/arm-aims-for-50-data-center-cpu-market-share-by-2025-challenging-intel-and-amd" target="_blank" rel="noreferrer noopener">Arm Aims for 50% Data Center CPU Market Share by 2025, Challenging Intel and AMD</a>
Other investors in the group are Microsoft, Coatue Management, Altimeter Capital Management, and Thrive Capital.
A second round of funding, totaling $30 billion, is expected by the end of 2025. This will consist of $22.5 billion from SoftBank and $7.5 billion from the investor group, the report noted.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters:&nbsp; OpenAI reportedly expects its revenue to surge to $12.7 billion this year. The company also revealed it has 1 million paid users for its corporate versions of ChatGPT, with a new $200-per-month "Pro" plan for access to advanced AI models.
On Monday, OpenAI CEO Sam Altman also announced plans to <a href="https://www.benzinga.com/tech/25/03/44577187/sam-altman-led-openai-releases-open-weight-ai-model-with-reasoning-capabilities-as-deepseek-and-meta-taste-success">release a new open-weight</a> language model with reasoning capabilities.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/03/44554189/openai-and-microsoft-back-mcp-standard-in-major-shift-toward-interoperable-ai-agents-that-can-think-click-and-navigate-the-web-but-google-ceo-sundar-pichai-appears-to-be-mulling-over-it-in-shakespearean-fashion-to-mcp-or-not-to-mcp" target="_blank" rel="noreferrer noopener">OpenAI And Microsoft Back MCP Standard For Web-Surfing AI Agents; Google's Sundar Pichai Asks A Shakespearean Question</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Media

MSFT

SFTBF

SFTBY

OpenAI Finalizes $40 Billion Funding Round, Valuing Company At $300 Billion With Backing From SoftBank And Microsoft

Needham analyst David Saxon reiterates CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and maintains $11 price target.

CYRX

Needham Reiterates Buy on CryoPort, Maintains $11 Price Target

Under the joint venture agreement, effective March 31, 2025, Alcoa will own a 75 percent interest and continue as the managing operator and IGNIS EQT will own a 25 percent interest. Alcoa and IGNIS EQT contributed $81 (€75) million and $27 (€25) million, respectively, to form the joint venture and fund the operations. Additionally, up to $108 (€100) million may be funded by Alcoa as needed for operations with a priority position in future cash returns. Further funding requires agreement by both partners and the funding would be shared 75 percent by Alcoa and 25 percent by IGNIS EQT.

Alcoa Partners With IGNIS EQT In Joint Venture To Restart San Ciprián Smelter, Ensuring Long-Term Viability Of Operations

NIO Reports 26.7% Increase In March Vehicle Deliveries To 15,039 Vehicles

Shares of PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/25/03/44572437/calvin-klein-parent-pvh-shares-climb-on-strong-q4-fy25-eps-guidance-above-estimates">better-than-expected fourth-quarter financial results.</a>
Calvin Klein and Tommy Hilfiger parent company PVH reported quarterly earnings of $3.27 per share, which beat the analyst consensus estimate of $3.21. Quarterly revenue came in at $2.37 billion, which beat the analyst consensus estimate of $2.33 billion.
PVH shares jumped 15.2% to $74.50 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) gained 146.8% to $0.89 in pre-market trading after falling around 7% on Monday.</li>
<li>bioAffinity Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) rose 99.1% to $0.5176 in pre-market trading after the company reported a year-over-year increase in FY24 financial results.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) rose 46.6% to $68.99 in pre-market trading following strong FY sales results.</li>
<li>Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) gained 30% to $1.52 in pre-market trading after reporting fourth-quarter results.</li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) surged 28.5% to $1.00 in pre-market trading following a 9% decline on Monday.</li>
<li>Cloudastructure Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) rose 25% to $5.55 in pre-market trading after reporting 2024 year-end results.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) gained 23.6% to $103.19 in pre-market after jumping 735% on Monday.</li>
<li>ON24, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) gained 14.2% to $5.94 in pre-market trading.</li>
<li>Progress Software Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) gained 5.7% to $54.45 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cambium Networks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares fell 50.3% to $0.3490 in pre-market trading after the company announced that it will delay Form 10-K filing for fiscal year 2024.</li>
<li>1stdibs.Com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) fell 27% to $2.22 in pre-market trading.</li>
<li>Foghorn Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) declined 19.2% to $2.95 in pre-market trading.</li>
<li>Soluna Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) fell 18.5% to $0.52 in pre-market trading after dipping over 28% on Monday.</li>
<li>Lucas GC Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) dipped 18.2% to $0.40 in pre-market trading.</li>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) fell 13.1% to $7.71 in today's pre-market trading.</li>
<li>Sunstone Hotel Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) fell 9.7% to $8.50 in pre-market trading. Sunstone Hotel Investors will report financial results for the first quarter 2025 on Tuesday, May 6.</li>
<li>Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) shares tumbled 8.9% to $7.20 in pre-market trading after falling over 3% on Monday.</li>
<li>Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) shares dipped 8% to $10.24 in pre-market trading.</li>
<li>Excelerate Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) shares fell 6.8% to $26.74 in pre-market trading. Excelerate Energy announced the pricing of upsized public offering of class A common stock.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/news/earnings/25/03/44561974/how-to-earn-500-a-month-from-apple-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44561974/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

BIAF

CMBM

CSAI

DIBS

FHTX

LGCL

MVST

MYGN

NMAX

NUTX

ONTF

PRGS

RSLS

SLNH

TNMG

ZBIO

Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

WestPark Capital analyst Curtis Shauger initiates coverage on Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy rating and announces Price Target of $280.

Initiation

AMZN

WestPark Capital Initiates Coverage On Amazon.com with Buy Rating, Announces Price Target of $280

Press Releases

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Early Santa Claus Rally Highlights Power Nickel Inc. (TSXV: PNPN) and Other Stocks to Watch Now!

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Comments

Cadrenal Therapeutics

Noticias

Últimas noticias sobre Cadrenal Therapeutics (NASDAQ:CVKD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL